No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CRL240517C270000
- 0.32
- +0.22+220.00%
15min DelayClose May 15 15:58 ET
0.32High0.32Low
0.32Open0.10Pre Close3 Volume301 Open Interest270.00Strike Price96.00Turnover132.41%IV16.29%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.32Time Value100Contract SizeAmericanOptions Type0.0529Delta0.0052Gamma516.80Leverage Ratio-0.4306Theta0.0005Rho27.34Eff Leverage0.0170Vega
Intraday
- 5D
- 1D
News
Insider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)
Charles River(CRL.US) Officer Sells US$295.97K in Common Stock
$Charles River(CRL.US)$ Officer LaPlume Joseph W sold 1,304 shares of common stock on May 10, 2024 at an average price of $226.97 for a total value of $295.97K.Source: Announcement What is statement o
Charles River Labs Is Maintained at Hold by TD Cowen
Charles River Labs Is Maintained at Hold by TD Cowen
Charles River Labs Price Target Cut to $228.00/Share From $260.00 by TD Cowen
Charles River Labs Price Target Cut to $228.00/Share From $260.00 by TD Cowen
Express News | TD Cowen Maintains Hold on Charles River, Lowers Price Target to $228
Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock
Comments
The CEOs of both Wheeler Bio and Charles River express optimism about the partnership, believing that the integration of discovery CRO and CDMO workflows will speed up the path to first-in-human trials and bring new treatments to patients faster.
Press Release: Wheeler Bio Seals Agreement With Charles River to Offer Portable CMC(R) to Discovery Clients to Accelerate Their Journey to First-in-Human UseInsider's recent share sale, even below current price, suggests satisfaction with lower valuation. Despite high insider ownership, this selling hints at caution. The company also has 1 warning sign worth noting before buying shares.
EPS growth outshines the yearly share price gain of 12%, indicating market caution towards the stock. Despite sell-off, long term shareholders gained 12% annually over five years, suggesting the sell-off might be a growth opportunity.
1
Charles River Laboratories International's high P/E ratio is concerning due to its lower than expected growth. Investors seem more bullish than analysts, but current prices may not be sustainable without significant improvement.
The recent and long-term insider transactions demonstrate a positive outlook about the company. The significant insider ownership of the company also indicates well-aligned incentives between the management and shareholders. Charles River Laboratories International may potentially be a promising investment.
Read more